Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin in Pediatric Subjects with BMI ≥ 85th Percentile [Internet]
P. Brian Smith(Duke University), Karen Martz(Emmes (United States)), Michael Cohen‐Wolkowiez(Duke University), Ravinder Anand(Population Health Research Institute), Daniel González(University of North Carolina at Chapel Hill), Michael J. Smith(Duke University)
Unknown
October 15, 2015
Cited by 0
Related Papers
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
|Obesity|2021|199
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
|Clinical Therapeutics|2016|170
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
|Circulation|2023|153